February 10, 2023 | Post ASH CME Series 2022: Multiple Myeloma

February 10, 2023 | Post ASH CME Series 2022: Multiple Myeloma

February 17, 2023 | Post ASH CME Series 2022: Classical HematologyПодробнее

February 17, 2023 | Post ASH CME Series 2022: Classical Hematology

Multiple Myeloma: An update from ASH - Dec 2022Подробнее

Multiple Myeloma: An update from ASH - Dec 2022

Multiple Myeloma: a post-ASH22 summaryПодробнее

Multiple Myeloma: a post-ASH22 summary

Revlimid Refractory Patients in Daratumumab Clinical Trials | Binod Dhakal, MD | ASH 2022Подробнее

Revlimid Refractory Patients in Daratumumab Clinical Trials | Binod Dhakal, MD | ASH 2022

Top Myeloma Research Presented at ASH 2022Подробнее

Top Myeloma Research Presented at ASH 2022

Post BCMA Therapy | Gurbakhash Kaur, MD | ASH 2022Подробнее

Post BCMA Therapy | Gurbakhash Kaur, MD | ASH 2022

ASH 2023 Multiple Myeloma Highlights – PERSEUS, IsKia, Bortezomib dosing, KarMMA-3Подробнее

ASH 2023 Multiple Myeloma Highlights – PERSEUS, IsKia, Bortezomib dosing, KarMMA-3

Is more better? Using quadruplet in frontline Multiple MyelomaПодробнее

Is more better? Using quadruplet in frontline Multiple Myeloma

Frailty and Multiple Myeloma | Hira Mian, MD, MSc | ASH 2022Подробнее

Frailty and Multiple Myeloma | Hira Mian, MD, MSc | ASH 2022

Exciting updates in R/R multiple myeloma: highlights at ASH 2022Подробнее

Exciting updates in R/R multiple myeloma: highlights at ASH 2022

Tom Brokaw discusses being diagnosed with Multiple Myeloma #shortsПодробнее

Tom Brokaw discusses being diagnosed with Multiple Myeloma #shorts

FAQs From the 2022 American Society of Hematology Annual MeetingПодробнее

FAQs From the 2022 American Society of Hematology Annual Meeting

Daratumumab, Carfilzomib, Lenalidomide and Dex for HR Smoldering Multiple Myeloma: ASCENT TrialПодробнее

Daratumumab, Carfilzomib, Lenalidomide and Dex for HR Smoldering Multiple Myeloma: ASCENT Trial

February 25, 2022 | Yale ASH 2021Highlights: Multiple MyelomaПодробнее

February 25, 2022 | Yale ASH 2021Highlights: Multiple Myeloma

Efficacy of Reduced Dosing of Talquetamab in Relapsed Refractory Myeloma | Ajai Chari, MD | ASH 2023Подробнее

Efficacy of Reduced Dosing of Talquetamab in Relapsed Refractory Myeloma | Ajai Chari, MD | ASH 2023

Multiple Myeloma Update | Shaji Kumar, MD | 2022 West Oncology | Updates for APPs & NursesПодробнее

Multiple Myeloma Update | Shaji Kumar, MD | 2022 West Oncology | Updates for APPs & Nurses

The IACH Post ASCO/EHA 2022 Roundtable Discussion: a Focus on Multiple MyelomaПодробнее

The IACH Post ASCO/EHA 2022 Roundtable Discussion: a Focus on Multiple Myeloma

Outcomes of BCMA-exposed vs BCMA-naïve patients with R/R multiple myelomaПодробнее

Outcomes of BCMA-exposed vs BCMA-naïve patients with R/R multiple myeloma

Tandem transplantation for patients with myeloma with high-risk cytogeneticsПодробнее

Tandem transplantation for patients with myeloma with high-risk cytogenetics

Актуальное